We previously reported that these synaptic proteins (SNAP25, GAP43, neurogranin, and synaptotagmin 1) in neuronal-derived extracellular vesicles (EVs) were significantly lower in AD than in healthy controls, and the combination of these proteins can predict AD 5 to 7 years before symptom appearance [22], indicating their roles as potential therapeutic targets for AD. This evidence concerns the gene GAP43 and Alzheimer disease.